Health-related quality of life measures in genetic disorders: An outcome variable for consideration in clinical trials

American Journal of Medical Genetics, Part C: Seminars in Medical Genetics

Volumn 151, Issue 3, 2009, Pages 255-260

  Stevenson, David A ^a   Carey, John C ^b  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF UTAH HEALTH SCIENCES CENTER   (United States)

Author keywords

Clinical trials; NF1; Quality of life

Indexed keywords

ARTICLE; BONE DYSPLASIA; CLINICAL TRIAL; COGNITIVE DEFECT; FUNCTIONAL ASSESSMENT; GENE; GENETIC DISORDER; HUMAN; MOBILIZATION; NF1 GENE; PAIN; PHYSICAL DISEASE; PRIORITY JOURNAL; PROGNOSIS; PSEUDARTHROSIS; QUALITY OF LIFE; TIBIA;

BONE DISEASES, DEVELOPMENTAL; CHILD; CLINICAL TRIALS AS TOPIC; GENETIC DISEASES, INBORN; GENETIC SERVICES; HEALTH STATUS; HUMANS; NEUROFIBROMATOSIS 1; NEUROFIBROMIN 1; OUTCOME ASSESSMENT (HEALTH CARE); QUALITY OF LIFE; RESEARCH DESIGN; TIBIA; TIME FACTORS;

MURINAE;

EID: 67651245405     PISSN: 15524868     EISSN: 15524876     Source Type: Journal    
DOI: 10.1002/ajmg.c.30217     Document Type: Article

References (43)

1. Anderson DJ, Schoenecker PL, Sheridan JJ, Rich MM. 1992. Use of an intermedullary rod for the treatment of congenital pseudarthrosis of the tibia. J Bone Joint Surg Am 74:161-168.
2. Bara T, Sibiński M, Synder M. 2007. Own clinical experience with functional bracing for treatment of pseudarthrosis and delayed union of the tibia. Ortop Traumatol Rehabil 9:259-263.
3. Barton B, North K. 2007. The self-concept of children and adolescents with neurofibromatosis type 1. Child Care Health Dev 33:410-418.
4. Bjoraker KJ, Delaney K, Peters C, Krivit W, Shapiro EG. 2006. Long-term outcomes of adaptive functions for children with mucopolysaccharidosis I (Hurler syndrome) treated with hematopoietic stem cell transplantation. J Dev Behav Pediatr 27:290-296.
5. Carey JC, Stevenson DA, Viskochil DH, Siebert J, Geyer S, Winn M, Roach J, D'Astous J, Marra C, Colley L, Friedman J, Birch P, Schorry E, and the TD Working Group. 2007. Quality of life investigation of tibial dysplasia in NF1 patients shows differences in outcome and provides a framework for clinical trials. Presented at the 2007 American Society of Human Genetics meeting. Abstract 645, p. 152.
6. Cawthon RM, Weiss R, Xu GF, Viskochil D, Culver M, Stevens J, Robertson M, Dunn D, Gesteland R, O'Connell P, White R. 1990. A major segment of the neurofibromatosis type 1 gene: cDNA sequence, genomic structure, and point mutations. Cell 62:193-201.
7. Coleman SS, Coleman DA, Biddulph G. 1995. Congenital pseudarthrosis of the tibia: Current concepts of treatment. Adv Oper Orthop 3:121-145.
8. Crawford AH, Schorry EK. 1997. Neurofibromatosis in children; the role of the orthopaedist. J Am Acad Orthop Surg 7:217-230.
9. Daltroy LH, Liang MH, Fossel AH, Goldberg MJ, and the Pediatric Outcomes Instrument Development Group. 1998. The POSNA musculoskeletal functional health questionnaire: Report on reliability, validity, and sensitivity to change. J Pediatr Ortho 18:561-571.
10. Dobbs MB, Rich MM, Gordon JE, Szymanski DA, Schoenecker PL. 2004. Use of an intrmedullary rod for the treatment of congenital pseudarthrosis of the tibia: A long-term follow-up study. J Bone Joint Surg Am 86:1186-1197.
11. Eiser C, Morse R. 2001. A review of measures of quality of life for children with chronic illness. Arch Dis Child 84:205-211.
12. Field RE, Buchanan JA, Copplemans MG, Aichroth PM. 1994. Bone-marrow transplantation in Hurler's syndrome. Effect on skeletal development. J Bone Joint Surg Br 76:975-981.
13. Friedlaender GE, Perry CR, Cole JD, Cook SD, Cierny G, Muschler GF, Zych GA, Calhoun JH, LaForte AJ, Yin S. 2001. Osteogenic protein-1 (bone morphogenetic protein-7) in the treatment of tibial nonunions. J Bone Joint Surg Am 83:S151-158.
14. Friedman JM, Birch PH. 1997. Type 1 Neurofibromatosis: A descriptive analysis of the disorder in 1728 patients. Am J Med Genet 70:138-143.
15. Furlong W, Barr RD, Feeny D, Yandow S. 2005. Patient-focused measures of functional health status and health-related quality of life in pediatric orthopedics: A case study in measurement selection. Health Qual Life Outcomes 3:3.
16. Gilbert A, Brockman R. 1995. Congenital pseudarthrosis of the tibia. Long-term followup of 29 cases treated by microvascular bone transfer. Clin Orthop Relat Res 314:37-44.
17. Graf A, Landolt MA, Mori AC, Boltshauser E. 2006. Quality of life and psychological adjustment in children and adolescents with neurofibromatosis type 1. J Pediatr 149: 348-353.
18. Grill F, Bollini G, Dungl P, Fixsen J, Hefti F, Ippolito E, Romanus B, Tudisco C, Wientroub S. 2000. Treatment approaches for congenital pseudarthrosis of tibia: Results of the EPOS multicenter study. J Pediatric Ortho Part B 9:75-89.
19. Gutmann DH, Aylsworth A, Carey JC, Korf B, Marks J, Pyeritz RE, Rubenstein A, Viskochil D. 1997. The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2. JAMA 278:51-57.
20. Hefti F, Bollini G, Dungl P, Fixsen J, Grill F, Ippolito E, Romanus B, Tudisco C, Wientroub S. 2000. Congenital pseudarthrosis of the tibia: History, etiology, classification, and epidemiologic data. J Ped Orthop 9:11-15.
21. Johnson EE, Urist MR, Finerham GAM. 1990. Distal metaphyseal tibial nonunion. Deformity and bone loss treated by open reduction, internal fixation, and human BMP. Clin Orthop 250:234-240.
22. Krab LC, de Goede-Bolder A, Aarsen FK, Pluijm SM, Bouman MJ, van der Geest JN, Lequin M, Catsman CE, Arts WF, Kushner SA, Silva AJ, de Zeeuw CI, Moll HA, Elgersma Y. 2008. Effect of simvastatin on cognitive functioning in children with neurofibromatosis type 1: A randomized controlled trial. JAMA 300:287-294.
23. Krab LC, Oostenbrink R, De Goede-Bolder A, Aarsen FK, Elgersma Y, Moll HA. 2009. Health-related quality of life in children with neurofibromatosis type 1: Contribution of demographic factors, disease-related factors, and behavior. J Pediatr 154:420-425.
24. Lacro RV, Dietz HC, Wruck LM, Bradley TJ, Colan SD, Devereux RB, Klein GL, Li JS, Minich LL, Paridon SM, Pearson GD, Printz BF, Pyeritz RE, Radojewski E, Roman MJ, Saul JP, Stylianou MP, Mahony L, Pediatric Heart Network Investigators. 2007. Rationale and design of a randomized clinical trial of beta-blocker therapy (atenolol) versus angiotensin II receptor blocker therapy (losartan) in individuals with Marfan syndrome. Am Heart J 154:624-631.
25. Miners AH, Sabin CA, Tolley KH, Jenkinson C, Kind P, Lee CA. 1999. Assessing health-related quality-of-life in individuals with haemophilia. Haemophilia 5:378-385.
26. Murray HH, Lovell WW. 1982. Congenital pseudarthrosis of the tibia: A Long-term follow-up study. Clinical Orthop Relat Res 166:14-20.
27. Neville C, Clarke AE, Joseph L, Belisle P, Ferland D, Fortin PR. 2000. Learning from discordance in patient and physician global assessments of systemic lupus erythematosus disease activity. J Rheumatol 27:675-679.
28. Ohnishi I, Sato W, Matsuyama J, Yajima H, Haga N, Kamegaya M, Minami A, Sato M, Yoshino S, Oki T, Nakamura K. 2005. Treatment of congenital pseudarthrosis of the tibia: A multicenter study in Japan. J Pediatr Orthop 25:219-224.
29. Oostenbrink R, Spong K, de Goede-Bolder A, Landgraf JM, Raat H, Moll HA. 2007. Parental reports of health-related quality of life in young children with neurofibromatosis type 1: Influence of condition specific determinants. J Pediatr 151:182-186.
30. Opitz JM, Carey JC. 2007. Genetics and the Wiley bicentanary: A brief look backwards, or the origin of Mendelism from morphology, and present and future perspectives. Am J Med Genet Part A 143:i-v.
31. Page PZ, Page GP, Ecosse E, Korf BR, Leplege A, Wolkenstein P. 2006. Impact of neurofibromatosis 1 on Quality of Life: A cross-sectional study of 176 American cases. Am J Med Genet Part A 140:1893-1898.
32. Plotkin H, Rauch F, Bishop NJ, Montpetit K, Ruck-Gibis J, Travers R, Glorieux FH. 2000. Pamidronate treatment of severe osteogenesis imperfecta in children under 3 years of age. J Clin Endocrinol Metab 85:1846-1850.
33. Romanus B, Bollini G, Dungl P, Fixsen J, Grill F, Hefti F, Ippolito E, Tudisco C, Wientroub S. 2000. Free vascular fibular transfer in congenital pseudoarthrosis of the tibia: Results of the EPOS multicenter study. European Paediatric Orthopaedic Society (EPOS). J Pediatr Orthop B 9:90-93.
34. Schiffmann R, Kopp JB, Austin HAIII, Sabnis S, Moore DF, Weibel T, Balow JE, Brady RO. 2001. Enzyme replacement therapy in Fabry disease: A randomized controlled trial. JAMA 285:2743-2749.
35. Stevenson DA, Birch PH, Friedman JM, Viskochil DH, Balestrazzi P, Boni S, Buske A, Korf BR, Niimura M, Pivnick EK, Schorry EK, Short MP, Tenconi R, Tonsgard JH, Carey JC. 1999. Descriptive analysis of tibial pseudarthrosis in patients with neurofibromatosis 1. Am J Med Genet Part A 84:413-419.
36. Sztajnbok F, Coronel-Martinez DL, Diaz-Maldonado A, Novarini C, Pistorio A, Viola S, Ruperto N, Buoncompagni A, Martini A, Ravelli A. 2007. Discordance between physician's and parent's global assessments in juvenile idiopathic arthritis. Rheumatology (Oxford) 46:141-145.
37. Traub JA, O'Connor W, Masso PD. 1999. Congenital pseudarthrosis of the tibia: A retrospective review. J Pediatr Orthop 19: 735-738.
38. Tudisco C, Bollini G, Dungl P, Fixen J, Grill F, Hefti F, Romanus B, Wientroub S. 2000. Functional results at the end of skeletal growth in 30 patients affected by congenital pseudoarthrosis of the tibia. J Pediatr Orthop B 9:94-102.
39. Viskochil D, Buchberg AM, Xu G, Cawthon RM, Stevens J,Wolff RK, Culver M, Carey JC, Copeland NG, Jenkins NA, White R, O'Connell P. 1990. Deletions and a translocation interrupt a cloned gene at the neurofibromatosis type 1 locus. Cell 62: 187-192.
40. Vitale MG, Levy DE, Moskowitz AJ, Gelijns AC, Spellmann M, Verdisco L, Roye DPJr. 2001. Capturing quality of life in pediatric orthopaedics: Two recent measures compared. J Pediatr Ortho 21:629-635.
41. von Satzger G, Herbst E. 1981. Surgical and electrical methods in the treatment of congenital and posttraumatic pseduarthrosis of the tibia. Clin Orthop Relat Res 161:82-104.
42. Wilson IB, Cleary PD. 1995. Linking clinical variables with health-related quality of life: A conceptual model of patient outcomes. JAMA 273:59-65.
43. Wolkenstein P, Zeller J, Revuz J, Ecosse E, Leplège A. 2001. Quality-of-life impairment in neurofibromatosis type 1: A cross-sectional study of 128 cases. Arch Dermatol 137:1421-1425.